{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:45:56Z","timestamp":1787755556332,"version":"build-2784847793"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,19]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Osteosarcoma and Ewing sarcoma are the 2 most common primary bone sarcomas, occurring predominantly in pediatric patients, with the incidence of osteosarcoma correlating with periods of peak bone-growth velocity. Although survival outcomes have plateaued over the past several decades, ongoing treatment advances have improved function, decreased infection rates, and improved other clinical outcomes in patients with bone tumors. Recently, the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial addressed the serious problem of surgical site infection (SSI) and the lack of consensus regarding the appropriate prophylactic postoperative antibiotic regimen. The objective of the present secondary analysis of the PARITY trial was to characterize the modern treatment and surgical and oncologic outcomes of pediatric patients with bone tumors at 1 year postoperatively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The PARITY trial included patients \u226512 years old with a bone tumor or soft-tissue sarcoma that was invading the femur or tibia, necessitating osseous resection and endoprosthetic reconstruction. This pediatric subanalysis of the PARITY trial data included all PARITY patients \u226418 years old. As in the main PARITY study, patients were randomized to either a 5-day or 1-day course of postoperative antibiotic prophylaxis. The primary outcome measure was the development of an SSI within 1 year, and secondary outcomes included antibiotic-related adverse events, unplanned additional operations, local recurrence, metastasis, and death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 151 patients were included. An adjudicated SSI occurred in 27 patients (17.9%). There was no difference in the rate of any SSI between the 5-day and 1-day antibiotic groups (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.4 to 1.9; p = 0.82). Antibiotic-related complications occurred in 13 patients (8.6%), with no difference noted between groups (HR, 0.46; 95% CI, 0.2 to 1.4; p = 0.18). A total of 45 patients (29.8%) required a return to the operating room within the first postoperative year, which corresponded with a 68.8% reoperation-free rate of survival at 1 year when accounting for competing risks. The most common reason for reoperation was infection (29 of 45; 64.4%). A total of 7 patients (4.6%) required subsequent amputation of the operative extremity, and an additional 6 patients (4.0%) required implant revision within 12 months. A total of 36 patients (23.8%) developed metastases, and 6 patients (4.0%) developed a local recurrence during the first postoperative year. A total of 11 patients (7.3%) died during the study period. There were no significant differences in oncologic outcomes between the 5-day and 1-day antibiotic groups (HR, 0.97; 95% CI, 0.5-1.8; p = 0.92).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>There were no significant differences in surgical or oncologic outcomes between pediatric patients who underwent a 1-day versus 5-day antibiotic regimen following endoprosthetic reconstruction in the PARITY trial. Surgeons should be aware of and counsel patients and caregivers regarding the 30% rate of reoperation and the risks of infection (17.9%), death (7.3%), amputation (4.6%), and implant revision (4%) within the first postoperative year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>\n                      Therapeutic\n                      <jats:underline>Level III<\/jats:underline>\n                      . See Instructions for Authors for a complete description of levels of evidence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2106\/jbjs.22.01231","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T11:09:38Z","timestamp":1689764978000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Operative Treatment and Outcomes of Pediatric Patients with an Extremity Bone Tumor"],"prefix":"10.2106","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8195-2086","authenticated-orcid":false,"given":"Anthony","family":"Bozzo","sequence":"first","affiliation":[{"name":"Division of Musculoskeletal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-2867","authenticated-orcid":false,"given":"Caleb M.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Van De Sande","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Leiden University Medical Center, Leiden, the Netherland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-4522","authenticated-orcid":false,"given":"Michelle","family":"Ghert","sequence":"additional","affiliation":[{"name":"Division of Orthopaedic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Healey","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PARITY Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"bib1-20250430","doi-asserted-by":"crossref","first-page":"548151","DOI":"10.1155\/2011\/548151","article-title":"Using epidemiology and genomics to understand osteosarcoma etiology","volume":"2011","author":"Savage","year":"2011","journal-title":"Sarcoma."},{"issue":"6","key":"bib2-20250430","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/MPH.0b013e318168e7dc","article-title":"Osteosarcoma developed in the period of maximal growth rate have inferior prognosis","volume":"30","author":"Lee","year":"2008","journal-title":"J Pediatr Hematol Oncol."},{"issue":"10","key":"bib4-20250430","first-page":"705","article-title":"Osteosarcoma: a review of diagnosis, management, and treatment strategies","volume":"8","author":"Geller","year":"2010","journal-title":"Clin Adv Hematol Oncol."},{"key":"bib5-20250430","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-4615-3518-8_37","article-title":"Osteosarcoma of the extremities: chemotherapy experience at Memorial Sloan-Kettering","volume":"62","author":"Meyers","year":"1993","journal-title":"Cancer Treat Res."},{"issue":"1","key":"bib6-20250430","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MPH.0000000000000456","article-title":"Ewing sarcoma: A 15-year experience of a single center with the MSKCC P6 treatment protocol","volume":"38","author":"Ben-Ami","year":"2016","journal-title":"J Pediatr Hematol Oncol."},{"issue":"3","key":"bib7-20250430","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"Oncologist."},{"issue":"1","key":"bib8-20250430","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1302\/0301-620X.84B1.0840088","article-title":"Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy","volume":"84","author":"Bacci","year":"2002","journal-title":"J Bone Joint Surg Br."},{"issue":"6","key":"bib9-20250430","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1302\/0301-620X.90B6.19805","article-title":"Limb-sparing surgery preserves more function than amputation: a Scandinavian sarcoma group study of 118 patients","volume":"90","author":"Aksnes","year":"2008","journal-title":"J Bone Joint Surg Br."},{"issue":"1","key":"bib10-20250430","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MOP.0b013e328334581f","article-title":"Pediatric osteogenic sarcoma","volume":"22","author":"Kim","year":"2010","journal-title":"Curr Opin Pediatr."},{"issue":"1","key":"bib11-20250430","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bjps.2015.08.035","article-title":"Pediatric lower extremity sarcoma reconstruction: A review of limb salvage procedures and outcomes","volume":"69","author":"Piper","year":"2016","journal-title":"J Plast Reconstr Aesthet Surg."},{"issue":"6","key":"bib12-20250430","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00590-017-1998-5","article-title":"Distraction osteogenesis reconstruction of large segmental bone defects after primary tumor resection: pitfalls and benefits","volume":"27","author":"Lesensky","year":"2017","journal-title":"Eur J Orthop Surg Traumatol."},{"issue":"8","key":"bib13-20250430","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1302\/0301-620X.84B8.0841162","article-title":"Osteosarcoma around the knee. Intraepiphyseal excision and biological reconstruction with distraction osteogenesis","volume":"84","author":"Tsuchiya","year":"2002","journal-title":"J Bone Joint Surg Br."},{"issue":"1","key":"bib14-20250430","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ocl.2006.10.008","article-title":"A new reconstructive technique for intercalary defects of long bones: the association of massive allograft with vascularized fibular autograft. Long-term results and comparison with alternative techniques","volume":"38","author":"Capanna","year":"2007","journal-title":"Orthop Clin North Am."},{"issue":"3","key":"bib15-20250430","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s11999-015-4204-2","article-title":"What is the outcome of allograft and intramedullary free fibula (Capanna technique) in pediatric and adolescent patients with bone tumors?","volume":"474","author":"Houdek","year":"2016","journal-title":"Clin Orthop Relat Res."},{"issue":"3","key":"bib16-20250430","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0030-5898(20)32095-2","article-title":"Endoprosthetic bone reconstruction following malignant tumor resection in skeletally immature patients","volume":"27","author":"Ward","year":"1996","journal-title":"Orthop Clin North Am."},{"issue":"6","key":"bib17-20250430","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2106\/JBJS.F.01324","article-title":"Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis","volume":"90","author":"Jeys","year":"2008","journal-title":"J Bone Joint Surg Am."},{"issue":"15","key":"bib18-20250430","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.3390\/jcm11154612","article-title":"Endoprosthetic Reconstruction in Ewing\u2019s Sarcoma Patients: A Systematic Review of Postoperative Complications and Functional Outcomes","volume":"11","author":"Abu El Afieh","year":"2022","journal-title":"J Clin Med."},{"issue":"1","key":"bib19-20250430","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2474-13-91","article-title":"Prophylactic antibiotic regimens in tumor surgery (PARITY) survey","volume":"13","author":"Hasan","year":"2012","journal-title":"BMC Musculoskelet Disord."},{"issue":"3","key":"bib20-20250430","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamaoncol.2021.6628","article-title":"Comparison of prophylactic intravenous antibiotic regimens after endoprosthetic reconstruction for lower extremity bone tumors: a randomized clinical trial","volume":"8","author":"Ghert","year":"2022","journal-title":"JAMA Oncol."},{"issue":"6","key":"bib21-20250430","doi-asserted-by":"crossref","first-page":"e002197","DOI":"10.1136\/bmjopen-2012-002197","article-title":"Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study","volume":"2","author":"Ghert","year":"2012","journal-title":"BMJ Open."},{"issue":"8","key":"bib22-20250430","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1302\/2046-3758.58.BJR-2016-0036.R1","article-title":"The inter-rater reliability of the diagnosis of surgical site infection in the context of a clinical trial","volume":"5","author":"Nuttall","year":"2016","journal-title":"Bone Joint Res."},{"issue":"4","key":"bib24-20250430","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ctrv.2013.11.006","article-title":"Osteosarcoma treatment - where do we stand? A state of the art review","volume":"40","author":"Luetke","year":"2014","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"bib25-20250430","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2008.14.0095","article-title":"Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival\u2014a report from the Children\u2019s Oncology Group","volume":"26","author":"Meyers","year":"2008","journal-title":"J Clin Oncol."},{"issue":"2","key":"bib26-20250430","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.2106\/JBJS.RVW.O.00013","article-title":"Surgical and functional outcomes after limb-preservation surgery for tumor in pediatric patients: a systematic review","volume":"4","author":"Groundland","year":"2016","journal-title":"JBJS Rev."},{"key":"bib27-20250430","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","article-title":"Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort","volume":"109","author":"Smeland","year":"2019","journal-title":"Eur J Cancer."},{"issue":"8","key":"bib28-20250430","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/cncr.10861","article-title":"Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience","volume":"95","author":"Aung","year":"2002","journal-title":"Cancer."},{"issue":"5","key":"bib29-20250430","doi-asserted-by":"crossref","first-page":"e207259","DOI":"10.1001\/jamasurg.2020.7259","article-title":"Effect of intrawound vancomycin powder in operatively treated high-risk tibia fractures: a randomized clinical trial","volume":"156","author":"O\u2019Toole","year":"2021","journal-title":"JAMA Surg."},{"issue":"3","key":"bib30-20250430","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00586-014-3357-0","article-title":"Intrawound vancomycin to prevent infections after spine surgery: a systematic review and meta-analysis","volume":"24","author":"Evaniew","year":"2015","journal-title":"Eur Spine J."},{"issue":"25","key":"bib31-20250430","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/BRS.0000000000000015","article-title":"Effects of using intravenous antibiotic only versus local intrawound vancomycin antibiotic powder application in addition to intravenous antibiotics on postoperative infection in spine surgery in 907 patients","volume":"38","author":"Tubaki","year":"2013","journal-title":"Spine (Phila Pa 1976)."},{"issue":"9","key":"bib32-20250430","first-page":"e28881","article-title":"Prophylactic Intrawound Vancomycin Powder in Minimally Invasive Spine Stabilization May Cause an Acute Inflammatory Response","volume":"14","author":"Hyodo","year":"2022","journal-title":"Cureus."},{"issue":"7","key":"bib33-20250430","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/BRS.0000000000000241","article-title":"Intraoperative vancomycin use in spinal surgery: single institution experience and microbial trends","volume":"39","author":"Ghobrial","year":"2014","journal-title":"Spine (Phila Pa 1976)."},{"issue":"9","key":"bib34-20250430","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3390\/cancers13091990","article-title":"Infectious morbidity in pediatric patients receiving neoadjuvant chemotherapy for sarcoma","volume":"13","author":"Willmer","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"33","key":"bib35-20250430","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children\u2019s Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J Clin Oncol."},{"issue":"3","key":"bib36-20250430","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3892\/mco.2015.528","article-title":"Postoperative infection and survival in osteosarcoma patients: Reconsideration of immunotherapy for osteosarcoma","volume":"3","author":"Chen","year":"2015","journal-title":"Mol Clin Oncol."},{"issue":"12","key":"bib37-20250430","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3390\/nu10121900","article-title":"Risk factors for surgical site infection after soft-tissue sarcoma resection, including the preoperative geriatric nutritional risk index","volume":"10","author":"Sasaki","year":"2018","journal-title":"Nutrients."},{"key":"bib38-20250430","doi-asserted-by":"crossref","first-page":"100345","DOI":"10.1016\/j.jbo.2020.100345","article-title":"Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: A review","volume":"26","author":"Phull","year":"2020","journal-title":"J Bone Oncol."},{"issue":"2","key":"bib39-20250430","first-page":"271","article-title":"Infection in orthopaedic oncology: crucial problem in modern reconstructive techniques","volume":"23","author":"Trovarelli","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"6","key":"bib40-20250430","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/jbji.39050","article-title":"Antimicrobial Prophylaxis for the Prevention of Surgical Site Infections in Orthopaedic Oncology - A Narrative Review of Current Concepts","volume":"4","author":"M\u00fcller","year":"2019","journal-title":"J Bone Jt Infect."},{"issue":"20","key":"bib41-20250430","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.2106\/JBJS.19.00182","article-title":"Musculoskeletal infection in orthopaedic oncology: assessment of the 2018 International Consensus Meeting on Musculoskeletal Infection","volume":"101","author":"Strony","year":"2019","journal-title":"J Bone Joint Surg Am."},{"issue":"3","key":"bib42-20250430","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","article-title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols","volume":"20","author":"Bielack","year":"2002","journal-title":"J Clin Oncol."},{"issue":"13","key":"bib43-20250430","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.2106\/JBJS.L.01189","article-title":"Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database","volume":"95","author":"Miller","year":"2013","journal-title":"J Bone Joint Surg Am."},{"issue":"8","key":"bib44-20250430","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.2003.08.165","article-title":"Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651","volume":"21","author":"Goorin","year":"2003","journal-title":"J Clin Oncol."},{"issue":"4","key":"bib45-20250430","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.JAA.0000531052.82007.42","article-title":"Update on surgical site infections: The new CDC guidelines","volume":"31","author":"Borchardt","year":"2018","journal-title":"JAAPA."},{"issue":"7","key":"bib46-20250430","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1245\/ASO.2003.07.023","article-title":"Prospective identification of risk factors for wound infection after lower extremity oncologic surgery","volume":"10","author":"Morris","year":"2003","journal-title":"Ann Surg Oncol."}],"container-title":["Journal of Bone and Joint Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.22.01231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:44:46Z","timestamp":1787751886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.22.01231"}},"subtitle":["A Secondary Analysis of the PARITY Trial Data"],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":44,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.22.01231","relation":{},"ISSN":["0021-9355","1535-1386"],"issn-type":[{"value":"0021-9355","type":"print"},{"value":"1535-1386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]}}}